ALDX vs. CVAC, LENZ, CALT, ELVN, MAZE, DNTH, PRAX, NUVB, COLL, and WVE
Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include CureVac (CVAC), LENZ Therapeutics (LENZ), Calliditas Therapeutics AB (publ) (CALT), Enliven Therapeutics (ELVN), Maze Therapeutics (MAZE), Dianthus Therapeutics (DNTH), Praxis Precision Medicines (PRAX), Nuvation Bio (NUVB), Collegium Pharmaceutical (COLL), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.
Aldeyra Therapeutics vs. Its Competitors
Aldeyra Therapeutics (NASDAQ:ALDX) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.
CureVac has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Aldeyra Therapeutics currently has a consensus target price of $9.50, indicating a potential upside of 69.34%. CureVac has a consensus target price of $6.83, indicating a potential upside of 25.84%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than CureVac.
CureVac has a net margin of 38.21% compared to Aldeyra Therapeutics' net margin of 0.00%. CureVac's return on equity of 29.57% beat Aldeyra Therapeutics' return on equity.
59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 8.5% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Aldeyra Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, CureVac has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500.
In the previous week, CureVac had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 3 mentions for CureVac and 2 mentions for Aldeyra Therapeutics. CureVac's average media sentiment score of 0.98 beat Aldeyra Therapeutics' score of 0.89 indicating that CureVac is being referred to more favorably in the news media.
Summary
CureVac beats Aldeyra Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Aldeyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aldeyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALDX) was last updated on 10/7/2025 by MarketBeat.com Staff
